Hereditary retinoblastoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:357027OMIM:180200C69.2
Who is this for?
Show terms as
23Active trials49Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hereditary retinoblastoma is a type of eye cancer that develops in the retina, the light-sensitive tissue at the back of the eye. It is caused by an inherited change (mutation) in the RB1 gene, which normally acts as a tumor suppressor — meaning it helps prevent cells from growing out of control. When a child inherits a faulty copy of this gene from a parent, every cell in their body carries that mutation, making them much more likely to develop tumors in one or both eyes, usually before the age of five. The most common early sign is a white glow in the pupil of the eye, often noticed in photographs taken with a flash. This is sometimes called "cat's eye reflex" or leukocoria. Other signs include crossed eyes (strabismus), redness, swelling, or vision problems. Because the mutation is present in all cells, children with hereditary retinoblastoma often develop tumors in both eyes and may also be at increased risk for other cancers later in life, such as bone cancer (osteosarcoma) or soft tissue sarcomas. Treatment depends on the size and location of the tumors and whether one or both eyes are affected. Options include chemotherapy (given through a vein, directly into the eye, or into the artery feeding the eye), laser therapy, cryotherapy (freezing treatment), radiation therapy, and in some cases surgical removal of the eye (enucleation). With early detection and modern treatments, survival rates are very high — over 95% in developed countries. Lifelong monitoring is essential because of the risk of new tumors and second cancers.

Key symptoms:

White glow or reflection in the pupil (leukocoria)Crossed eyes or misaligned eyes (strabismus)Redness or swelling of the eyePoor vision or vision lossEye painDifferent-colored irises (heterochromia)Enlarged pupilBulging of the eye in advanced casesTumors in both eyes (bilateral involvement)Failure to track objects with the eyesIncreased risk of second cancers later in life (bone cancer, soft tissue sarcoma, melanoma)

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.

University of Washington

TrialRECRUITING
Apr 2025High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

Eye & ENT Hospital of Fudan University — EARLY_PHASE1

TrialRECRUITING
Feb 2025Retinoblastoma Phase II Expanded Access Clinical Trial

Targeted Therapy Technologies, LLC — PHASE2

TrialRECRUITING
Dec 2024Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

Eye & ENT Hospital of Fudan University — EARLY_PHASE1

TrialRECRUITING
Jan 2024Trilateral Retinoblastoma: Incidence and Outcomes

Amsterdam UMC, location VUmc

TrialRECRUITING
Oct 2023Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors

Amsterdam University Medical Center

TrialENROLLING BY INVITATION
Nov 2022A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Children's Oncology Group — PHASE2

TrialRECRUITING
Mar 2021Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

Institut Curie — PHASE2, PHASE3

TrialRECRUITING
Mar 2021Topotecan and Melphalan for Retinoblastoma

Sun Yat-sen University — PHASE3

TrialRECRUITING
Nov 2020Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma

French Africa Pediatric Oncology Group

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Hereditary retinoblastoma.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →
Phase 33 trials
Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation
Phase 3
Active
PI: Huasheng Yang, Doctor (Zhongshan Ophthalmic Center, Sun Yat-sen Universit) · Sites: Guangzhou, Guangdong
Topotecan and Melphalan for Retinoblastoma
Phase 3
Actively Recruiting
PI: Huashen Yang (Sun Yat-sen University) · Sites: Guangzhou, Guangdong
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
Phase 3
Actively Recruiting
PI: Huasheng Yang, M.D, PHD (Zhongshan Ophthalmic Center, Sun Yat-sen Universit) · Sites: Guangzhou, Guangdong
Phase 26 trials
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)
Phase 2
Active
· Sites: Saint-Denis, La Réunion; Amiens +25 more · Age: 010 yrs
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
Phase 2
Active
PI: Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital) · Sites: Memphis, Tennessee
Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma
Phase 2
Active
PI: Brenda L Gallie, MD (The Hospital for Sick Children) · Sites: Vancouver, British Columbia; Toronto, Ontario +4 more
Retinoblastoma Phase II Expanded Access Clinical Trial
Phase 2
Actively Recruiting
· Sites: New York, New York · Age: 08 yrs
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Phase 2
Actively Recruiting
PI: Rachana Shah (Children's Oncology Group) · Sites: Birmingham, Alabama; Los Angeles, California +18 more · Age: 018 yrs
Conservative Treatments of Retinoblastoma
Phase 2
Active
PI: Isabelle Aerts, MD (Institut Curie - Paris - France) · Sites: Paris · Age: 06 yrs
Other10 trials
Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?
Actively Recruiting
PI: Augustin Lecler, MD (Fondation OPH A de Rothschild) · Sites: Paris
Trilateral Retinoblastoma: Incidence and Outcomes
Actively Recruiting
PI: Marcus de Jong, MD PhD (Amsterdam UMC) · Sites: Amsterdam, North Holland
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.
Actively Recruiting
PI: Debarshi Mustafi, MD PhD (University of Washington) · Sites: Seattle, Washington
Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life
Active
PI: Danielle Novetsky Friedman, MD (Memorial Sloan Kettering Cancer Center) · Sites: New York, New York · Age: 1899 yrs
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Enrolling by Invitation
PI: Annette C. Moll, MD PhD (Amsterdam University Medical Center) · Sites: Amsterdam, North Holland · Age: 035 yrs
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Actively Recruiting
PI: Rosandra N Kaplan, M.D. (National Cancer Institute (NCI)) · Sites: Washington D.C., District of Columbia; Orange, Florida +3 more
RB Liquid Biopsy Biorepository
Actively Recruiting
PI: Jesse L Berry, MD (Children's Hospital Los Angeles) · Sites: Los Angeles, California · Age: 018 yrs
Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients
Actively Recruiting
PI: Vittoria Arslan Carlon, MD (Memorial Sloan Kettering Cancer Center) · Sites: New York, New York · Age: 617 yrs
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
Actively Recruiting
PI: Debra Friedman, MD (Vanderbilt Medical Center) · Sites: Chicago, Illinois; Chicago, Illinois +9 more
Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
Actively Recruiting
PI: FOUSSEYNI Mr TRAORE, Dr; (AMCC AND GFAOP) · Sites: Ouagadougou; Abidjan +5 more · Age: 018 yrs

Specialists

Showing 25 of 49View all specialists →
HY
Huashen Yang
Specialist
PI on 1 active trial481 Hereditary retinoblastoma publications
RS
Rachana Shah
Specialist
PI on 1 active trial112 Hereditary retinoblastoma publications
GM
Guillermo L Chantada, MD
Specialist
PI on 1 active trial1 Hereditary retinoblastoma publication
JM
Jesse L Berry, MD
Specialist
PI on 1 active trial
MM
Margaret Reynolds, M.D.
Specialist
PI on 1 active trial
SM
Sara M. Federico, MD
MEMPHIS, TN
Specialist
PI on 3 active trials
DM
Danielle Novetsky Friedman, MD
Specialist
PI on 1 active trial
CM
Carlos Rodriguez-Galindo, MD
MEMPHIS, TN
Specialist
PI on 4 active trials
RM
Rosandra N Kaplan, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 4 active trials
KM
Kim E. Nichols, MD
Memphis, Tennessee
Specialist

Rare Disease Specialist

PI on 2 active trials
HM
Hervé BRISSE, MD
Specialist
PI on 1 active trial
CM
Catherine Albert, MD
Specialist
PI on 3 active trials
LM
Lisa Wray, MD
Specialist
PI on 1 active trial1 Hereditary retinoblastoma publication
MM
Muna Qayed, MD
ATLANTA, GA
Specialist
PI on 2 active trials
AM
Andrew Cluster, M.D.
SAINT LOUIS, MO
Specialist
PI on 2 active trials
RM
Rachel Brennan, MD
Specialist
PI on 2 active trials
AM
Ashish Gupta, MBBS, MPH
Specialist
PI on 4 active trials
GB
Greta Bunin
Specialist
PI on 1 active trial1 Hereditary retinoblastoma publication
KP
KiWoong Sung, MD, PhD
Specialist
PI on 1 active trial
AM
Andrew W Stacey, MD
ANN ARBOR, MI
Specialist
PI on 1 active trial1 Hereditary retinoblastoma publication
DP
Debarshi Mustafi, MD PhD
SEATTLE, WA
Specialist
PI on 1 active trial
PG
Pim de Graaf
Specialist
PI on 1 active trial
LR
Livia LUMBROSO LE ROUIC
Specialist
PI on 1 active trial
JG
James Geller
SAN DIEGO, CA
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hereditary retinoblastoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hereditary retinoblastomaForum →

No community posts yet. Be the first to share your experience with Hereditary retinoblastoma.

Start the conversation →

Latest news about Hereditary retinoblastoma

Disease timeline:

New recruiting trial: Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: Topotecan and Melphalan for Retinoblastoma

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: Retinoblastoma Phase II Expanded Access Clinical Trial

A new clinical trial is recruiting patients for Hereditary retinoblastoma

New recruiting trial: Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

A new clinical trial is recruiting patients for Hereditary retinoblastoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What is the exact RB1 mutation in my child, and should other family members be tested?,What treatment plan do you recommend, and what are the chances of saving my child's vision?,How often will my child need eye exams under anesthesia, and for how long?,What is my child's risk of developing second cancers, and what screening should be done throughout their life?,Are there clinical trials or newer treatments available that might benefit my child?,What support services are available for our family, including genetic counseling and psychological support?,If we plan to have more children, what are the chances they will also have this condition, and what prenatal testing options exist?

Common questions about Hereditary retinoblastoma

What is Hereditary retinoblastoma?

Hereditary retinoblastoma is a type of eye cancer that develops in the retina, the light-sensitive tissue at the back of the eye. It is caused by an inherited change (mutation) in the RB1 gene, which normally acts as a tumor suppressor — meaning it helps prevent cells from growing out of control. When a child inherits a faulty copy of this gene from a parent, every cell in their body carries that mutation, making them much more likely to develop tumors in one or both eyes, usually before the age of five. The most common early sign is a white glow in the pupil of the eye, often noticed in phot

How is Hereditary retinoblastoma inherited?

Hereditary retinoblastoma follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Hereditary retinoblastoma typically begin?

Typical onset of Hereditary retinoblastoma is infantile. Age of onset can vary across affected individuals.

Are there clinical trials for Hereditary retinoblastoma?

Yes — 20 recruiting clinical trials are currently listed for Hereditary retinoblastoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Hereditary retinoblastoma?

25 specialists and care centers treating Hereditary retinoblastoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.